Usefulness of Neurofilaments in Serum and Cerebrospinal Fluid as Biomarker for Tunisian Patients with Amyotrophic Lateral Sclerosis
Imen Kacem1, Ikram Sghaier1, Kouloud Takout2, Youssef Abida1, Alya Gharbi1, Amira Souissi1, Amina Gargouri Ep Berrechid1, Riadh Gouider1
1Neurology Department, LR18SP03 and Clinical Investigation Center Neuroscience and Mental Health - Razi University Hospital - La Mannouba, Tunis, Tunisia, 2Faculté des Sciences de Tunis, Université Tunis El Manar
Objective:

Comparison of CSF and blood neurofilament light (NfL) and heavy chain (NfH) as prognostic biomarker for ALS

Background:
Amyotrophic Lateral Sclerosis (ALS) is an incurable neurodegenerative disease marked by motor neuron degeneration. Recent advancements identify neurofilaments (Nfs) as potential biomarkers in cerebrospinal fluid and blood, with significantly elevated levels in ALS.
Design/Methods:

We conducted a prospective study involving patients diagnosed with ALS according to the Gold Coast criteria at Razi University Hospital in Tunisia. Participants were classified based on their rates of disease progression. We measured NfL and NfH levels in both cerebrospinal fluid (CSF) and blood using ELISA technology. Subsequently, we examined the correlation between Nfs levels in CSF and blood, as well as their relationship with various clinical features of ALS

Results:

We included 40patients with a mean age at onset of 54.24 years and a sex ratio of 1.78. Of these patients, 34 had spinal ALS and 6 with bulbar onset.

Measurements of Nfs showed a strong correlation between cerebrospinal fluid (CSF) and blood (rho=0.836, p<0.0001 for NfL and rho=0.641, p<0.01 for NfH). We found a significant association between NfL concentrations and bulbar onset (rho=0.493, p<0.0001; rho=0.525, p<0.0001). Conversely, the correlation between NfL values in both biofluids and ALSFRS-R scores was weaker (rho=0.206, p=0.023; rho=0.217, p=0.006). Furthermore, patients with rapid progression, regardless of ALS subtype, exhibited higher NfL levels than those with slower progression (p=0.026).

Regarding Neurofilament Heavy Chain (NfH), we observed elevated levels in ALS patients, along with a strong correlation between NfL and NfH values. Additionally, NfH levels were negatively correlated with the ALS disease course (rho=-0.72, p=0.036).

 
Conclusions:

Nfs are effective ALS biomarkers, with high levels linked to disease onset, progression, and ALSFRS-R scores. Blood is preferred for Nfs measurement due to its non-invasive nature, showing similar results to CSF.

 

10.1212/WNL.0000000000211234
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.